GP681 40mg

DRUG3 trials

Sponsors

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Conditions

InfluenzaInfluenza, Human

Phase 3

To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection

CompletedNCT05474755

Jiangxi Qingfeng Pharmaceutical Co. Ltd.Influenza

Start: 2022-07-28End: 2023-10-31Updated: 2023-11-14

Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications

RecruitingNCT06573008

Jiangxi Qingfeng Pharmaceutical Co. Ltd.Influenza, Human

Start: 2024-11-11End: 2025-12-30Target: 328Updated: 2024-12-04

Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza

RecruitingNCT06574503

Jiangxi Qingfeng Pharmaceutical Co. Ltd.Influenza

Start: 2024-12-01End: 2027-12-30Target: 748Updated: 2024-12-05

Related Papers

Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

2025-01-076 citations